metadata
library_name: setfit
tags:
- setfit
- sentence-transformers
- text-classification
- generated_from_setfit_trainer
datasets:
- CabraVC/vector_dataset_stratified_ttv_split_2023-12-05_21-07
metrics:
- accuracy
widget:
- text: >-
for the taliglucerase alfa NDA that set forth additional requirements for
approval. Protalix will work with the FDA to determine next steps.
In May 2010, the FDA issued a “complete response” letter requesting
additional information in connection with our supplemental NDA seeking
approval to use Sutent for the treatment of pancreatic neuroendocrine
tumors. We have provided the requested information, including an analysis
of independently reviewed scans, and are working with the FDA to pursue
regulatory approval.
In April 2010, we received a “complete response” letter from the FDA for
the Genotropin Mark VII multidose disposable device submission. In August
2010, we submitted our response to address the requests and
recommendations included in the FDA letter.
In June 2010, we received a “complete response” letter from the FDA for
the Celebrex chronic pain supplemental NDA. We are working with the FDA to
determine the next steps.
In October 2009, we received a “complete response” letter from the FDA
with respect to the supplemental NDA for Geodon for the treatment of acute
bipolar mania in children and adolescents aged 10 to 17 years. In October
2010, we submitted our response to address the issues raised in the FDA
letter. In April 2010, we received a “warning letter” from the FDA with
respect to the clinical trial in support of this supplemental NDA. We are
working with the FDA to address the issues raised in the letter.
Boehringer Ingelheim (BI), our alliance partner, holds the NDAs for
Spiriva Handihaler and Spiriva Respimat. In September 2008, BI received a
“complete response” letter from the FDA for the Spiriva Respimat
submission. The FDA is seeking additional data, and we are coordinating
with BI, which is working with the FDA to provide the additional
information. A full response will be submitted to the FDA upon the
completion of planned and ongoing studies.
In September 2007, we received an “approvable” letter from the FDA for
Zmax that set forth requirements to obtain approval for the pediatric
acute otitis media (AOM) indication based on pharmacokinetic data. A
supplemental filing for pediatric AOM and sinusitis remains under review.
Two “approvable” letters were received by Wyeth in April and December 2007
from the FDA for Viviant (bazedoxifene), for the prevention of
post-menopausal osteoporosis, that set forth the additional requirements
for approval. In May 2008, Wyeth received an “approvable” letter from the
FDA for the treatment of post-menopausal osteoporosis. The FDA is seeking
additional data, and we have been systematically working through these
requirements and seeking to address the FDA’s concerns. In February 2008,
the FDA advised Wyeth that it expects to convene an advisory committee to
review the pending NDAs for both the treatment and prevention indications
after we submit our response to the “approvable” letters. In April 2009,
Wyeth received approval in the EU for CONBRIZA (the EU trade name for
Viviant) for the treatment of post-menopausal osteoporosis in women at
increased risk of fracture. Viviant was also approved in Japan in July
2010 for the treatment of post-menopausal osteoporosis.
In July 2007,
- text: "year 2005, offset by a $663 million decline in Upgrade Advantage earned revenue. \n\nInformation Worker operating income increased in fiscal year 2006 primarily due to the revenue growth, partially offset by a $283 million or 15% increase in sales and marketing expenses related to supporting field sales efforts and a $71 million or 10% increase in research and development expenses. Headcount-related costs increased 14% during fiscal year 2006 reflecting both an 18% increase in headcount related to supporting field sales efforts and research and development investments in future products and an increase in salaries and benefits for existing headcount, partially offset by a decrease in stock-based compensation expense. Information Worker operating income growth for fiscal year 2005 was primarily due to the revenue growth and a $304 million decrease in stock-based compensation expense. Operating expenses were also impacted by a reduction in marketing campaign costs from the previous period associated with the launch of Office 2003. This decline was offset by an increase in headcount-related costs as a result of an increase in headcount and an increase in salaries and benefits for existing headcount. \n\n\_\n\nMicrosoft Business Solutions \n\n\_\n\nMicrosoft Business Solutions provides business management software solutions targeted to businesses of varying sizes. The main products consist of enterprise resource planning (“ERP”) solutions, customer relationship management (“CRM”) software, retail solutions, Microsoft Partner Program (“MSPP”), and related services. Microsoft Business Solutions also includes the Small\n\n\n\n\n\n\_\n\n\_\n\n\_\n\nand Mid-market Solutions and Partners (“SMS&P”), which focuses on sales to customers and partners in the small and mid-market customer segments. Revenue is derived from software and services sales, with software sales representing a significant amount of total revenue. Software revenues include both new software licenses and enhancement plans, which provide customers with future software upgrades over the period of the plan. Our solutions are delivered through a worldwide network of channel partners that provide services and local support. \n\nMicrosoft Business Solutions revenue increased in fiscal year 2006 driven by new users for Microsoft CRM and existing Dynamics ERP customers purchasing functionality and user licenses. The increase in Microsoft Business Solutions revenue in fiscal year 2005 was mainly due to 10% revenue growth in software partially offset by 25% decline in services revenue. The software revenue increase was driven by 9% growth in license revenue and 16% growth in enhancement revenue and was attributed to growth in ERP and CRM solutions and an increase in MSPP subscriptions. \n\nMicrosoft Business Solutions operating income increased in fiscal year 2006 reflecting the increase in revenue accompanied by a $56 million decrease in sales and marketing expense as a result of decreased net SMS&P spending.\_Headcount-related costs increased 3% reflecting both a 10% increase in headcount and an increase in salaries and benefits for existing headcount, partially offset by a decrease in stock-based compensation expense."
- text: "2004\n\n\n\nManagement's Discussion and Analysis of Financial Condition and Results of Operations\n\nThis section and other parts of this Form\_10-K contain forward-looking statements that involve risks and uncertainties. Forward-looking statements can also be identified by words such as \"anticipates,\" \"expects,\" \"believes,\" \"plans,\" \"predicts,\" and similar terms. Forward-looking statements are not guarantees of future performance and the Company's actual results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such differences include, but are not limited to, those discussed in the subsection entitled \"Factors That May Affect Future Results and Financial Condition\" below. The following discussion should be read in conjunction with the consolidated financial statements and notes thereto included in Item 8 of this Form\_10-K. All information presented herein is based on the Company's fiscal calendar. The Company assumes no obligation to revise or update any forward-looking statements for any reason, except as required by law.\n\nExecutive Overview\n\nApple designs, manufactures and markets personal computers and related software, services, peripherals and networking solutions. The Company also designs, develops and markets a line of portable digital music players along with related accessories and services including the online distribution of third-party music and audio books. The Company's products and services include the Macintosh line of desktop and notebook computers, the iPod digital music player, the Xserve server and Xserve RAID storage products, a portfolio of consumer and professional software applications, the Mac\_OS\_X operating system, the online iTunes Music Store, a portfolio of peripherals that support and enhance the Macintosh and iPod product lines, and a variety of other service and support offerings. The Company sells its products worldwide through its online stores, its own retail stores, its direct sales force, and third-party wholesalers, resellers and value added resellers. In addition, the Company sells a variety of third-party Macintosh compatible products, including computer printers and printing supplies, storage devices, computer memory, digital video and still cameras, personal digital assistants, and various other computing products and supplies through its online and retail stores. The Company sells to education, consumer, creative professional, business and government customers. A further description of the Company's products may be found in Part\_I, Item\_1 of this document under the heading \"Business.\"\n\nThe Company's business strategy leverages its unique ability, through the design and development of its own operating system, hardware and many software applications and technologies, to bring to its customers around the world compelling new products and solutions with superior ease-of-use, seamless integration and innovative industrial design.\n\nThe Company participates in several highly competitive markets, including personal computers with its Macintosh line of computers, consumer electronics with its iPod line of digital music players and distribution of"
- text: >-
we have access to significant distribution networks in rural and suburban
areas in Brazil and the opportunity to register and commercialize Teuto’s
products in various markets outside Brazil. For additional information,
see also Notes to Consolidated Financial Statements—Note 2D. Acquisitions,
Divestitures, Collaborative Arrangements and Equity-Method Investments:
Equity-Method Investments.
• On October 6, 2010, we completed our acquisition of FoldRx
Pharmaceuticals, Inc. (FoldRx), a privately held drug discovery and
clinical development company. FoldRx’s lead product candidate, Vyndaqel
(tafamidis meglumine), was approved in the EU in November 2011 and our new
drug application was accepted for review in the U.S. in February 2012.
This product is a first-in-class oral therapy for the treatment of
transthyretin familial amyloid polyneuropathy (TTR-FAP), a progressively
fatal genetic neurodegenerative disease, for which liver transplant is the
only treatment option currently available. Our acquisition of FoldRx has
increased our presence in the growing rare medical disease market, which
complements our Specialty Care unit. For additional information regarding
Vyndaqel (tafamidis meglumine), see the “Product
Developments—Biopharmaceutical” section of this Financial Review. The
total consideration for the acquisition was approximately $400 million.
For additional information about the acquisition, see Notes to
Consolidated Financial Statements—Note 2A. Acquisitions, Divestitures,
Collaborative Arrangements and Equity-Method Investments: Acquisitions.
Our Financial Guidance for 2013
We forecast 2013 revenues of $56.2 billion to $58.2 billion, Reported
diluted earnings per common share (EPS) of $1.50 to $1.65 and Adjusted
diluted EPS of $2.20 to $2.30. The exchange rates assumed in connection
with the 2013 financial guidance are as of mid-January 2013. For an
understanding of Adjusted income and Adjusted diluted EPS (both non-GAAP
financial measures), see the “Adjusted Income” section of this Financial
Review.
The 2013 financial guidance reflects the benefit of a full-year
contribution from Zoetis. We plan to update this guidance in April 2013 to
reflect the impact of the recent initial public offering (IPO) of an
approximate 19.8% ownership interest in Zoetis. For additional information
on the IPO, see Notes to Consolidated Financial Statements—Note 19A.
Subsequent Events: Zoetis Debt Offering and Initial Public Offering.
The following table provides a reconciliation of 2013 Adjusted income and
Adjusted diluted EPS guidance to 2013 Reported net income attributable to
Pfizer Inc. and Reported diluted EPS attributable to Pfizer Inc. common
shareholders guidance:
Our 2013 financial guidance is subject to a number of factors and
uncertainties—as described in the “Forward-Looking Information and Factors
That May Affect Future Results”, “Our Operating Environment” and “Our
Strategy” sections of this Financial Review and in Part I, Item 1A, “Risk
Factors”, of our 2012 Annual Report on Form 10-K.
SIGNIFICANT ACCOUNTING POLICIES AND APPLICATION OF CRITICAL ACCOUNTING
ESTIMATES
For a description of our significant accounting policies, see Notes to
- text: >-
as a component of Other (income) expense, net; and
a $ 56 million decrease in foreign exchange losses related to the
difference between actual foreign currency exchange rates and standard
foreign currency exchange rates assigned to the NIKE Brand geographic
operating segments and Converse, net of hedge gains; these losses are
reported as a component of consolidated gross margin.
Foreign Currency Exposures and Hedging Practices
Overview
As a global company with significant operations outside the United States,
in the normal course of business we are exposed to risk arising from
changes in currency exchange rates. Our primary foreign currency exposures
arise from the recording of transactions denominated in non-functional
currencies and the translation of foreign currency denominated results of
operations, financial position and cash flows into U.S. Dollars.
Our foreign exchange risk management program is intended to lessen both
the positive and negative effects of currency fluctuations on our
consolidated results of operations, financial position and cash flows. We
manage global foreign exchange risk centrally on a portfolio basis to
address those risks that are material to NIKE, Inc. We manage these
exposures by taking advantage of natural offsets and currency correlations
that exist within the portfolio and, where practical and material, by
hedging a portion of the remaining exposures using derivative instruments
such as forward contracts and options. As described below, the
implementation of the NIKE Trading Company (“NTC”) and our foreign
currency adjustment program enhanced our ability to manage our foreign
exchange risk by increasing the natural offsets and currency correlation
benefits that exist within our portfolio of foreign exchange exposures.
Our hedging policy is designed to partially or entirely offset the impact
of exchange rate changes on the underlying net exposures being hedged.
Where exposures are hedged, our program has the effect of delaying the
impact of exchange rate movements on our Consolidated Financial
Statements; the length of the delay is dependent upon hedge horizons. We
do not hold or issue derivative instruments for trading or speculative
purposes.
Transactional Exposures
We conduct business in various currencies and have transactions which
subject us to foreign currency risk. Our most significant transactional
foreign currency exposures are:
• Product Costs — NIKE’s product costs are exposed to fluctuations in
foreign currencies in the following ways:
Product purchases denominated in currencies other than the functional
currency of the transacting entity:
Certain NIKE entities, including those supporting our North America,
Greater China, Japan and European geographies, purchase product from the
NTC, a wholly-owned sourcing hub that buys NIKE branded products from
third-party factories, predominantly in U.S. Dollars. The NTC, whose
functional currency is the U.S. Dollar, then sells the products to NIKE
entities in their respective functional currencies. When the NTC sells to
a NIKE entity with a different functional currency, the result is a
foreign currency exposure for the NTC.
Other
pipeline_tag: text-classification
inference: true
model-index:
- name: SetFit
results:
- task:
type: text-classification
name: Text Classification
dataset:
name: CabraVC/vector_dataset_stratified_ttv_split_2023-12-05_21-07
type: CabraVC/vector_dataset_stratified_ttv_split_2023-12-05_21-07
split: test
metrics:
- type: accuracy
value: 0.4583333333333333
name: Accuracy
SetFit
This is a SetFit model trained on the CabraVC/vector_dataset_stratified_ttv_split_2023-12-05_21-07 dataset that can be used for Text Classification. A LogisticRegression instance is used for classification.
The model has been trained using an efficient few-shot learning technique that involves:
- Fine-tuning a Sentence Transformer with contrastive learning.
- Training a classification head with features from the fine-tuned Sentence Transformer.
Model Details
Model Description
- Model Type: SetFit
- Classification head: a LogisticRegression instance
- Maximum Sequence Length: 512 tokens
- Number of Classes: 3 classes
- Training Dataset: CabraVC/vector_dataset_stratified_ttv_split_2023-12-05_21-07
Model Sources
- Repository: SetFit on GitHub
- Paper: Efficient Few-Shot Learning Without Prompts
- Blogpost: SetFit: Efficient Few-Shot Learning Without Prompts
Model Labels
| Label | Examples |
|---|---|
| BUY |
|
| SELL |
|
| HOLD |
|
Evaluation
Metrics
| Label | Accuracy |
|---|---|
| all | 0.4583 |
Uses
Direct Use for Inference
First install the SetFit library:
pip install setfit
Then you can load this model and run inference.
from setfit import SetFitModel
# Download from the 🤗 Hub
model = SetFitModel.from_pretrained("setfit_model_id")
# Run inference
preds = model("year 2005, offset by a $663 million decline in Upgrade Advantage earned revenue.
Information Worker operating income increased in fiscal year 2006 primarily due to the revenue growth, partially offset by a $283 million or 15% increase in sales and marketing expenses related to supporting field sales efforts and a $71 million or 10% increase in research and development expenses. Headcount-related costs increased 14% during fiscal year 2006 reflecting both an 18% increase in headcount related to supporting field sales efforts and research and development investments in future products and an increase in salaries and benefits for existing headcount, partially offset by a decrease in stock-based compensation expense. Information Worker operating income growth for fiscal year 2005 was primarily due to the revenue growth and a $304 million decrease in stock-based compensation expense. Operating expenses were also impacted by a reduction in marketing campaign costs from the previous period associated with the launch of Office 2003. This decline was offset by an increase in headcount-related costs as a result of an increase in headcount and an increase in salaries and benefits for existing headcount.
Microsoft Business Solutions
Microsoft Business Solutions provides business management software solutions targeted to businesses of varying sizes. The main products consist of enterprise resource planning (“ERP”) solutions, customer relationship management (“CRM”) software, retail solutions, Microsoft Partner Program (“MSPP”), and related services. Microsoft Business Solutions also includes the Small
and Mid-market Solutions and Partners (“SMS&P”), which focuses on sales to customers and partners in the small and mid-market customer segments. Revenue is derived from software and services sales, with software sales representing a significant amount of total revenue. Software revenues include both new software licenses and enhancement plans, which provide customers with future software upgrades over the period of the plan. Our solutions are delivered through a worldwide network of channel partners that provide services and local support.
Microsoft Business Solutions revenue increased in fiscal year 2006 driven by new users for Microsoft CRM and existing Dynamics ERP customers purchasing functionality and user licenses. The increase in Microsoft Business Solutions revenue in fiscal year 2005 was mainly due to 10% revenue growth in software partially offset by 25% decline in services revenue. The software revenue increase was driven by 9% growth in license revenue and 16% growth in enhancement revenue and was attributed to growth in ERP and CRM solutions and an increase in MSPP subscriptions.
Microsoft Business Solutions operating income increased in fiscal year 2006 reflecting the increase in revenue accompanied by a $56 million decrease in sales and marketing expense as a result of decreased net SMS&P spending. Headcount-related costs increased 3% reflecting both a 10% increase in headcount and an increase in salaries and benefits for existing headcount, partially offset by a decrease in stock-based compensation expense.")
Training Details
Training Set Metrics
| Training set | Min | Median | Max |
|---|---|---|---|
| Word count | 431 | 479.2917 | 532 |
| Label | Training Sample Count |
|---|---|
| BUY | 3 |
| HOLD | 6 |
| SELL | 15 |
Training Hyperparameters
- batch_size: (6, 8)
- num_epochs: (0, 32)
- max_steps: -1
- sampling_strategy: oversampling
- body_learning_rate: (0.0, 0.0)
- head_learning_rate: 0.0002
- loss: CosineSimilarityLoss
- distance_metric: cosine_distance
- margin: 0.25
- end_to_end: False
- use_amp: False
- warmup_proportion: 0.1
- l2_weight: 0.08
- max_length: 512
- seed: 1003200212
- eval_max_steps: -1
- load_best_model_at_end: False
Framework Versions
- Python: 3.11.6
- SetFit: 1.0.1
- Sentence Transformers: 2.2.2
- Transformers: 4.35.2
- PyTorch: 2.1.1
- Datasets: 2.15.0
- Tokenizers: 0.15.0
Citation
BibTeX
@article{https://doi.org/10.48550/arxiv.2209.11055,
doi = {10.48550/ARXIV.2209.11055},
url = {https://arxiv.org/abs/2209.11055},
author = {Tunstall, Lewis and Reimers, Nils and Jo, Unso Eun Seo and Bates, Luke and Korat, Daniel and Wasserblat, Moshe and Pereg, Oren},
keywords = {Computation and Language (cs.CL), FOS: Computer and information sciences, FOS: Computer and information sciences},
title = {Efficient Few-Shot Learning Without Prompts},
publisher = {arXiv},
year = {2022},
copyright = {Creative Commons Attribution 4.0 International}
}